BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20012148)

  • 1. Lead identification and optimization of diaminopyrimidines as histamine H4 receptor ligands.
    Sander K; Kottke T; Proschak E; Tanrikulu Y; Schneider EH; Seifert R; Schneider G; Stark H
    Inflamm Res; 2010 Mar; 59 Suppl 2():S249-51. PubMed ID: 20012148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.
    Sander K; Kottke T; Tanrikulu Y; Proschak E; Weizel L; Schneider EH; Seifert R; Schneider G; Stark H
    Bioorg Med Chem; 2009 Oct; 17(20):7186-96. PubMed ID: 19773175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.
    Hammer SG; Gobleder S; Naporra F; Wittmann HJ; Elz S; Heinrich MR; Strasser A
    Bioorg Med Chem Lett; 2016 Jan; 26(2):292-300. PubMed ID: 26718844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperazine modification in 2,4,6-triaminopyrimidine derivatives as histamine H4 receptor ligands.
    Schreeb A; Walter M; Odadzic D; Schwed JS; Weizel L; Stark H
    Pharmazie; 2013 Jul; 68(7):521-5. PubMed ID: 23923631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening.
    Kiss R; Kiss B; Könczöl A; Szalai F; Jelinek I; László V; Noszál B; Falus A; Keseru GM
    J Med Chem; 2008 Jun; 51(11):3145-53. PubMed ID: 18459760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major advances in the development of histamine H4 receptor ligands.
    Smits RA; Leurs R; de Esch IJ
    Drug Discov Today; 2009 Aug; 14(15-16):745-53. PubMed ID: 19477292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
    Mowbray CE; Bell AS; Clarke NP; Collins M; Jones RM; Lane CA; Liu WL; Newman SD; Paradowski M; Schenck EJ; Selby MD; Swain NA; Williams DH
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6596-602. PubMed ID: 21920751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H₄ receptor antagonists.
    Savall BM; Chavez F; Tays K; Dunford PJ; Cowden JM; Hack MD; Wolin RL; Thurmond RL; Edwards JP
    J Med Chem; 2014 Mar; 57(6):2429-39. PubMed ID: 24495018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand based design of novel histamine H₄ receptor antagonists; fragment optimization and analysis of binding kinetics.
    Smits RA; Lim HD; van der Meer T; Kuhne S; Bessembinder K; Zuiderveld OP; Wijtmans M; de Esch IJ; Leurs R
    Bioorg Med Chem Lett; 2012 Jan; 22(1):461-7. PubMed ID: 22153663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and functional characterization of imbutamine analogs as histamine H3 and H4 receptor ligands.
    Geyer R; Kaske M; Baumeister P; Buschauer A
    Arch Pharm (Weinheim); 2014 Feb; 347(2):77-88. PubMed ID: 24493592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.
    Savall BM; Edwards JP; Venable JD; Buzard DJ; Thurmond R; Hack M; McGovern P
    Bioorg Med Chem Lett; 2010 Jun; 20(11):3367-71. PubMed ID: 20452213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of a 2-benzothiazolylphenylmethyl ether class of histamine H4 receptor antagonists.
    Labeeuw O; Levoin N; Billot X; Danvy D; Calmels T; Krief S; Ligneau X; Berrebi-Bertrand I; Robert P; Lecomte JM; Schwartz JC; Capet M
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5263-5266. PubMed ID: 27692832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and pharmacological characterization of VUF14480, a covalent partial agonist that interacts with cysteine 98(3.36) of the human histamine H₄ receptor.
    Nijmeijer S; Engelhardt H; Schultes S; van de Stolpe AC; Lusink V; de Graaf C; Wijtmans M; Haaksma EE; de Esch IJ; Stachurski K; Vischer HF; Leurs R
    Br J Pharmacol; 2013 Sep; 170(1):89-100. PubMed ID: 23347159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of pK(a) on pyrimidine/pyridine-derived histamine H4 ligands.
    Savall BM; Meduna SP; Venable J; Wei J; Smith RC; Hack MD; Thurmond RL; McGovern P; Edwards JP
    Bioorg Med Chem Lett; 2014 Dec; 24(23):5489-92. PubMed ID: 25455490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histamine H4 receptor ligands and their potential therapeutic applications.
    Kiss R; Keseru GM
    Expert Opin Ther Pat; 2009 Feb; 19(2):119-35. PubMed ID: 19441913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Dynamic, Split-Luciferase-Based Mini-G Protein Sensor to Functionally Characterize Ligands at All Four Histamine Receptor Subtypes.
    Höring C; Seibel U; Tropmann K; Grätz L; Mönnich D; Pitzl S; Bernhardt G; Pockes S; Strasser A
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations.
    Krueger KM; Witte DG; Ireland-Denny L; Miller TR; Baranowski JL; Buckner S; Milicic I; Esbenshade TA; Hancock AA
    J Pharmacol Exp Ther; 2005 Jul; 314(1):271-81. PubMed ID: 15821027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profile of astemizole-derived compounds at the histamine H1 and H4 receptor--H1/H4 receptor selectivity.
    Wagner E; Wittmann HJ; Elz S; Strasser A
    Naunyn Schmiedebergs Arch Pharmacol; 2014 Mar; 387(3):235-50. PubMed ID: 24241585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
    Altenbach RJ; Adair RM; Bettencourt BM; Black LA; Fix-Stenzel SR; Gopalakrishnan SM; Hsieh GC; Liu H; Marsh KC; McPherson MJ; Milicic I; Miller TR; Vortherms TA; Warrior U; Wetter JM; Wishart N; Witte DG; Honore P; Esbenshade TA; Hancock AA; Brioni JD; Cowart MD
    J Med Chem; 2008 Oct; 51(20):6571-80. PubMed ID: 18811133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.